drugset
drugset / Trial / NCT03909295

An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.

NCT03909295 ↗

Phase 3 Terminated 52 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study evaluated the safety and tolerability of LCZ696 treatment in Japanese heart failure patients (NYHA Class II-IV) with preserved ejection fraction after CLCZ696D2301 (PARAGON-HF).

Timeline

Start
2019-05-07
Primary completion
2019-11-19
Completion
2019-11-19

Drugs

EvaluationDrugModalityDoseRoute
Subject LCZ696 Unknown 200 mg —

Indications

diastolic heart failure